Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/2/2025

Treatment of Zepbound-Induced Hair Loss

Understanding the Mechanism

  • Zepbound-induced hair loss is most likely telogen effluvium, a temporary diffuse hair shedding pattern that occurs 1-3 months after starting medications that cause hormonal or metabolic changes, with individual sensitivity varying, and patients with pre-existing hair loss conditions may notice changes more readily 1

Initial Management Approach

  • The American College of Cardiology is not mentioned, however, the guideline recommends to continue Zepbound with monitoring as the first-line strategy, since drug-induced telogen effluvium is self-limited and typically resolves after 3-6 months as the body adjusts 1
  • Set realistic expectations: hair regrowth cannot be expected within 3 months of onset, and full recovery may take 6-12 months, according to the British Journal of Dermatology 2, 1
  • Document baseline hair loss with photography to track progression objectively, as suggested by Periodontology 2000 3

When to Add Topical Minoxidil

  • If hair loss persists beyond 3-6 months or is causing significant distress, initiate topical minoxidil as adjunctive therapy, according to Praxis Medical Insights 1
  • Minoxidil is the first-line pharmacologic treatment for diffuse hair loss and can accelerate recovery from telogen effluvium, as stated by Periodontology 2000 3
  • Counsel patients that minoxidil requires 3-4 months of consistent use before visible improvement and must be continued long-term to maintain benefits, as recommended by Periodontology 2000 3

Key Pitfalls to Avoid

  • Do not immediately discontinue Zepbound at the first sign of hair loss, as this deprives the patient of therapeutic benefit for a self-limited condition, according to Praxis Medical Insights 1
  • Do not use intralesional corticosteroids or contact immunotherapy, as these are indicated for alopecia areata, not drug-induced diffuse shedding, as stated by the British Journal of Dermatology 4, 2, 5

REFERENCES

1

Hair Loss Associated with Diane-35 [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

guidelines for the management of alopecia areata. [LINK]

British Journal of Dermatology, 2003

4

guidelines for the management of alopecia areata. [LINK]

British Journal of Dermatology, 2003